Progenics Pharmaceuticals Reports Top Line Phase 3 Data For Prostate Cancer Imaging Agent 1404 | Latest News RSS feed

Progenics Pharmaceuticals Reports Top Line Phase 3 Data For Prostate Cancer Imaging Agent 1404 - Latest News


Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404

NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and ... read more

Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer

PyL is the Company's PSMA-targeted small molecule PET imaging agent designed to visualize prostate cancer ... of Progenics. "Our data from OSPREY provides strong rationale for continued development, ... read more

Progenics Pharmaceuticals Completes Enrollment of Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™ in Prostate Cancer

We look forward to reporting top-line data from the trial in the fourth quarter of 2018 while initiating a second Phase 3 ... PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) ... read more

Looking for another news?


Progenics Pharmaceuticals shares plummet after failed Phase 3 prostate cancer trial

Progenics Pharmaceuticals ... 1404 imaging agent was supposed to be able to detect prostate cancer with a 60% or higher sensitivity but fell in the range of 47% to 51%. "These top line Phase 3 results ... read more


Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404Top-line Data Expected in 3Q2018

NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals ... cancer, today announced that it has completed enrollment in its Phase 3 study of 1404, a PSMA-targeted small molecule SPECT/CT ... read more

Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404

Progenics Pharmaceuticals ... imaging analytical tools for targeting and treating cancer, today announced that it has completed enrollment in its Phase 3 study of 1404, a PSMA-targeted small molecule ... read more

Top-line Data Expected in 4Q2018

We look forward to reporting top-line data from the trial in the fourth quarter of 2018 while initiating a second Phase 3 ... PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) ... read more

Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404

NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. PGNX, -3.93% an oncology company developing innovative medicines and imaging analysis technology for targeting and treating ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us